Physician profile
Angela Pham
NPI 1972218543
$5,273.29
in general payments reported to CMS, 2019-2025
24 companies · $2,525 in 2025
The $2,525 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $968 · 2024: $1,780 · 2025: $2,525.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,273.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,273.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $779.76 | 2023-2025 | Ofev, Jascayd |
| Astrazeneca Pharmaceuticals LP | $604.90 | 2023-2025 | Breztri, Fasenra, Airsupra |
| Genzyme Corporation | $563.27 | 2023-2025 | |
| Actelion Pharmaceuticals US, INC. | $462.22 | 2023-2025 | Opsumit, Uptravi, Opsynvi |
| Jazz Pharmaceuticals INC. | $459.93 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $376.40 | 2023-2025 | Dupixent |
| Mylan Specialty L.P. | $345.70 | 2023-2024 | Yupelri |
| Glaxosmithkline, LLC. | $311.81 | 2024-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Ani Pharmaceuticals, INC. | $176.61 | 2024-2025 | Purified Cortrophin Gel |
| Viatris Specialty LLC | $160.42 | 2025 | Yupelri |
| Insmed, INC. | $145.61 | 2024-2025 | Arikayce, Brinsupri |
| Verona Pharma, INC. | $132.62 | 2025 | Ohtuvayre |
| Mallinckrodt Hospital Products INC. | $122.97 | 2023-2025 | Acthar |
| Harmony Biosciences LLC | $121.94 | 2023-2025 | Wakix |
| Grifols USA, LLC | $96.20 | 2024-2025 | Prolastin-C Liquid |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avadel Cns Pharmaceuticals, LLC | $89.38 | 2025 | Lumryz |
| Merck Sharp & Dohme LLC | $75.32 | 2023-2024 | Belsomra, Winrevair |
| United Therapeutics Corporation | $50.48 | 2024-2025 | Tyvaso, Tyvaso |
| Vifor Pharma, INC. | $46.95 | 2025 | Zemaira |
| Stryker Corporation | $46.63 | 2025 | Flowtriever |
| Amgen INC. | $37.97 | 2025 | Tezspire |
| Pulmonx Corporation | $30.08 | 2024 | Zephyr Endobronchial Valve, Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console |
| Axsome Therapeutics, INC. | $19.99 | 2024 | Sunosi |
| Lilly USA, LLC | $16.13 | 2025 | Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Pham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.